DCTD Biopharmaceutical development

Objectives

The Biopharmaceutical Development Program (BDP) supports development, manufacturing, and testing of new concepts in cancer therapeutics based on biological agents and biological response modifiers. Under the Economy in Government Act, BDP also performed reimbursed manufacturing activities for other institutes in support of clinical trials in Type I Diabetes and Malaria Vaccines.

BDP uses leading-edge technologies for the development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other biological agents.